Results 231 to 240 of about 250,661 (348)
Integrative Genomic and Single-Cell Insights Into Efferocytosis-Mediated Immune Regulation in Clear Cell Renal Cell Carcinoma. [PDF]
Shi B +11 more
europepmc +1 more source
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi +8 more
wiley +1 more source
BAP1 Loss as a Marker of Aggressive Clear Cell Renal Cell Carcinoma: Three Cases With Spinal Metastases. [PDF]
Alevizopoulos N +3 more
europepmc +1 more source
Photoacoustic Microscopy for Multiscale Biological System Visualization and Clinical Translation
Photoacoustic microscopy (PAM) is a powerful biomedical imaging tool renowned for its non‐invasiveness and high resolution. This review synthesizes recent technological advances and highlights their broad applications from cellular and organ‐level to whole‐animal imaging.
Tingting Wang +3 more
wiley +1 more source
A novel angiogenesis-related gene signature predicting prognosis in clear cell renal cell carcinoma. [PDF]
Xu YY, Cheng GB, Li XY, Zeng XX, Wu SY.
europepmc +1 more source
CXCR4 functions as a potential cancer stem cell‐associated marker linked to chemoresistance in ovarian cancer, and an inhibitor of CXCR4, AMD3100, can enhance the cytotoxic response to cisplatin. Based on these findings, [68Ga]Ga‐Pentixafor positron emission tomography enables selective visualization of CXCR4‐high ovarian cancer, while AMD3100 combined
Lixia Feng +12 more
wiley +1 more source
HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma. [PDF]
Mal A +21 more
europepmc +1 more source
Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao +14 more
wiley +1 more source

